The development of tyrosine kinase inhibitors for the treatment of inflammation and malignant disease.

开发用于治疗炎症和恶性疾病的酪氨酸激酶抑制剂。

• 批准号: LP0454363
• 负责人: Prof David Hume
• 金额: $ 18.8万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-08-31 至 2007-08-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0454363
• 关键词: development; tyrosine; kinase; inhibitors; treatment

Through the combination of expertise from the Industry partner and the Hume group this project aims to develop specific inhibitors of the CSF-1 receptor protein tyrosine kinase in order to demonstrate their efficacy as modulators of CSF-1 dependent macrophage and tumour cell function in vitro. The expected outcome will be a lead set of targets which can be further assessed for therapeutic potential in clinical trials.

通过行业合作伙伴和休谟小组的专业知识相结合，该项目旨在开发特定的CSF-1受体蛋白酪氨酸激酶抑制剂，以证明它们作为依赖于CSF-1的巨噬细胞和肿瘤细胞功能的体外调节剂的有效性。预期的结果将是一组领先的靶点，可以在临床试验中进一步评估治疗潜力。